Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Adjuvant and Down-Staging Treatment with Imatinib in Gastrointestinal Stromal Tumours
Linköpings universitet, Hälsouniversitetet, Hälsouniversitetets läkarutbildning.
2008 (Engelska)Självständigt arbete på avancerad nivå (yrkesexamen), 10 poäng / 15 hpStudentuppsats
Abstract [en]

Background: GISTs are gastrointestinal mesenchymal tumours that express the type III receptor tyrosine kinase KIT. The KIT proto-oncogene encodes the receptor KIT. Most GISTs have gain-of-function mutations in the KIT or PDGFRA gene. The tyrosine kinase is therefore continuously activated leading to ligand-independent dimerization. Imatinib mesylate (Glivec®) is considered to be the first-line palliative treatment. The activated form of the KIT receptor tyrosine kinase is inhibited by imatinib. The aim of the study was to compare the survival of patients treated with either adjuvant or down-staging imatinib with historic controls treated with radical surgery (R0) only.

Methods: A historic control group was chosen from a population-based series from western Sweden (population 1.6 million) that matched the adjuvant (n=23) and down-staging (n=7) groups respectively. Mutation analysis was performed in all cases with bidirectional direct sequencing. The recurrence-free survival was calculated.

Results: There was only one recurrence (4 %) in the adjuvant group, and no recurrences in the down-staging study group, compared to 32/48 patients (67 %) in the control group. Tumour size decreased in diameter from 20 cm to 11 cm with down-staging treatment.

Conclusion: Adjuvant imatinib improves recurrence-free survival in R0 resected patients. Down-staging treatment with imatinib is recommended for patients with large tumours or metastases. The importance of mutation analysis was established.

Ort, förlag, år, upplaga, sidor
Hälsouniversitetets läkarutbildning , 2008. , s. 25
Nyckelord [en]
GIST, imatinib, adjuvant, down-staging, neoadjuvant, mutation, KIT, PDGFRA
Nationell ämneskategori
Klinisk vetenskap
Identifikatorer
URN: urn:nbn:se:liu:diva-11060ISRN: LIU-LÄKARPRG-D--08/001--SEOAI: oai:DiVA.org:liu-11060DiVA, id: diva2:17512
Ämne / kurs
Läkarprogrammet, fördjupningsarbete (Advanced level)
Presentation
2007-11-28, 00:00
Uppsök
lantbruk/veterinärmed./skogl. vetenskap
Handledare
Examinatorer
Tillgänglig från: 2008-02-19 Skapad: 2008-02-19 Senast uppdaterad: 2012-04-24Bibliografiskt granskad

Open Access i DiVA

fulltext(2089 kB)759 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 2089 kBChecksumma MD5
8fd7a0b6c14971492fb9623395c5b1d9c3f399faf637e03595d82343b74813377b6fa456
Typ fulltextMimetyp application/pdf

Av organisationen
Hälsouniversitetets läkarutbildning
Klinisk vetenskap

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 759 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

urn-nbn

Altmetricpoäng

urn-nbn
Totalt: 1257 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf